cancer treatment $6m mkt cap looks cheap, page-3

quiet thread

good sign shows stock is yet to be discovered by hotcopperites
and stock is flying under the radar

should see a big rerate when the market catches on to the huge potential fee/royalty

"If exercised, Transgene may receive up to €700 million, plus royalties. Any funds Transgene were to receive upon exercise of this option during the term of the Virax Co-X
-Gene™ technology Sub-licence would result in payments under the licence"


Again that payment would be about $1.075 BILLION in AUD terms and even a few % of that to VHL would be many bags on current market cap